The NKG2A immune checkpoint — a new direction in cancer immunotherapy

被引：0
|
作者：
Benjamin C. Creelan
Scott J. Antonia
机构：
[1] H. Lee Moffitt Cancer Center & Research Institute,Thoracic Oncology Department
[2] Duke Cancer Institute,DCI Center for Cancer Immunology
来源：
Nature Reviews Clinical Oncology | 2019年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Inhibition of the NKG2A immune checkpoint restores natural killer cell and T cell effector function in preclinical cancer models. In addition, NKG2A blockade in combination with other therapeutic antibodies is showing encouraging responses in a subset of patients with metastatic colorectal or head and neck cancer. However, established biomarkers of response are lacking, and larger trials are needed to enable firm conclusions to be drawn about whether NKG2A inhibition complements existing immunotherapies.
引用
收藏
页码：277 / 278
页数：1
相关论文
共 50 条
  • [41] Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
    Liu, Rose
    Fernandez-Penas, Pablo
    Sebaratnam, Deshan F.
    MEDICAL JOURNAL OF AUSTRALIA, 2017, 206 (09)
  • [42] Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
    Bourke, Jack M.
    O'Sullivan, Michael
    Khattak, Muhammad A.
    MEDICAL JOURNAL OF AUSTRALIA, 2016, 205 (09) : 418 - 424
  • [43] The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression
    Eugene, Juliette
    Jouand, Nicolas
    Ducoin, Kathleen
    Dansette, Delphine
    Oger, Romain
    Deleine, Cecile
    Leveque, Edouard
    Meurette, Guillaume
    Podevin, Juliette
    Matysiak, Tamara
    Bennouna, Jaafar
    Bezieau, Stephane
    Volteau, Christelle
    Thomas, Wassila El Alami
    Chetritt, Jerome
    Kerdraon, Olivier
    Fourquier, Pierre
    Thibaudeau, Emilie
    Dumont, Frederic
    Mosnier, Jean-Francois
    Toquet, Claire
    Jarry, Anne
    Gervois, Nadine
    Bossard, Celine
    MODERN PATHOLOGY, 2020, 33 (03) : 468 - 482
  • [44] Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
    Priyatharcini Kejamurthy
    K. T. Ramya Devi
    Medical Oncology, 41
  • [45] CANCER IMMUNOTHERAPY Searching in the immune checkpoint black box
    Villanueva, M. Teresa
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (09) : 599 - 599
  • [46] Neurological complications of immune checkpoint inhibitor cancer immunotherapy
    Zivelonghi, Cecilia
    Zekeridou, Anastasia
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 424
  • [47] A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Chhabra, Neeraj
    Kennedy, Joseph
    JOURNAL OF MEDICAL TOXICOLOGY, 2021, 17 (04) : 411 - 424
  • [48] Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    Bai, Rilan
    Lv, Zheng
    Xu, Dongsheng
    Cui, Jiuwei
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [49] Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Bai, Jing
    Liang, Ping
    Li, Qian
    Feng, Rui
    Liu, Jiang
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2021, 16 (02) : 239 - 248
  • [50] Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
    Byun, David J.
    Wolchok, Jedd D.
    Rosenberg, Lynne M.
    Girotra, Monica
    NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) : 195 - 207
12345